Quick Answer
Pharma-Bio Serv, Inc. reported Operating Income Loss of -$637.7 thousand for the year ending 2025.
- Pharma-Bio Serv, Inc. showed an increase of +50.5% in Operating Income Loss from 2024 to 2025.
- This data is from Pharma-Bio Serv, Inc.'s annual report (Form 10-K), filed with the SEC on January 29, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $204.8 thousand | Q1 2011: $517.5 thousand | Q2 2011: $736.8 thousand | Q3 2011: $1.17 million | Q1 2012: $1.36 million | Q2 2012: $1.43 million | Q3 2012: $1.57 million | Q1 2013: $1.29 million | Q2 2013: $1.75 million | Q3 2013: $1.53 million | Q1 2014: $827.6 thousand | Q2 2014: $419.3 thousand | Q3 2014: $698.3 thousand | Q1 2015: $328.4 thousand | Q2 2015: $392.0 thousand | Q3 2015: $495.3 thousand | Q1 2016: $384.1 thousand | Q2 2016: $94.6 thousand | Q3 2016: -$120.8 thousand | Q1 2017: -$384.0 thousand | Q2 2017: -$324.6 thousand | Q3 2017: -$194.3 thousand | Q1 2018: -$2.47 million | Q2 2018: -$8.7 thousand | Q3 2018: $721.8 thousand | Q1 2019: $471.0 thousand | Q2 2019: $476.9 thousand | Q3 2019: $360.7 thousand | Q1 2020: $536.8 thousand | Q2 2020: $720.4 thousand | Q3 2020: $816.7 thousand | Q1 2021: $319.1 thousand | Q2 2021: $264.8 thousand | Q3 2021: $360.5 thousand | Q1 2022: $355.8 thousand | Q2 2022: $280.6 thousand | Q3 2022: $369.5 thousand | Q1 2023: $328.6 thousand | Q2 2023: $380.1 thousand | Q3 2023: $460.5 thousand | Q1 2024: -$438.3 thousand | Q2 2024: -$313.4 thousand | Q3 2024: -$381.8 thousand | Q1 2025: -$92.2 thousand | Q2 2025: -$98.3 thousand | Q3 2025: -$313.9 thousand | Q1 2026: -$94.5 thousand.
- Over the full 16 years of available data (2010 to 2025), Pharma-Bio Serv, Inc.'s Operating Income Loss has declined by 204.6%.
- Historical annual values: Fiscal year 2025: -$637.7 thousand | Fiscal year 2024: -$1.29 million | Fiscal year 2023: $1.12 million | Fiscal year 2022: $1.17 million | Fiscal year 2021: -$3.85 million | Fiscal year 2020: $2.23 million | Fiscal year 2019: $1.70 million | Fiscal year 2018: -$1.26 million | Fiscal year 2017: -$777.8 thousand | Fiscal year 2016: -$91.8 thousand | Fiscal year 2015: $1.78 million | Fiscal year 2014: $2.86 million | Fiscal year 2013: $6.07 million | Fiscal year 2012: $5.73 million | Fiscal year 2011: $3.45 million | Fiscal year 2010: $609.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: